Hearts & Minds' hearty donation for spinal cord injury research
Hearts & Minds' hearty donation for spinal cord injury research
About this video
Kathryn states that this injection of funds is one of the largest they've received this financial year and will vastly assist in their two priority research initiatives. SpinalCure Australia is currently focusing on the area of Neurostimulation, which has shown significant advancements in scientific breakthroughs over the past decade. Their current project, 'Project Spark', is rigorously testing this approach, with hopes of providing the evidence required for regulatory approval and something ready for mainstream use within a matter of years.
On the other side, Paul Rayson, CEO of Hearts and Minds Investments, highlights their commitment to directing research dollars to organisations with innovative research ideas like SpinalCure Australia. Hearts and Minds operates by investing in global equities chosen by select fund managers, without investment fees. Instead, 1.5% of the value of the company is donated to medical research annually, amounting to about $10 million per year. They've raised approximately $65 million since inception, with Spinal Cure Australia being the recent beneficiary of this unique investment approach.
Kathryn and Paul discuss the important potential of AI in advancing medical research, especially in this field. Kathryn also speaks of Elon Musk's ongoing clinical trial using a brain chip in quadriplegics to allow control of video games using their mind. Looking forward, Kathryn anticipates progressive steps towards mainstream therapies to restore feeling and function for individuals with spinal cord injuries. With the right level of funding and backing, she optimistically shares that a cure within this lifetime could be possible.
Find the full unedited transcript of this interview below:
Well now for the business of impact investing. Not for profit organisation Spinal Cure Australia will receive over $400,000 over the next two years from the ASX listed Hearts and Minds Investments, in order to accelerate its research projects into spinal cord injury research. To discuss the partnership, I'm joined by chief Executive Officer of Spinal Cure Australia, Kathryn Borkovic and Hearts and Minds CEO Paul Rayson. Good to have you both here. Thank you for having us today. Kathryn. I'll start with you. How significant is this injection for spinal cure? Look, the $400,000 from hearts and minds is actually one of our largest donations this financial year. So pretty, pretty significant. And it will go towards our two priority research projects that are funding a cure for spinal cord injuries. So just tell us where you're at with the research, because I imagine this is something that is going to take a long time and need a lot of investment. That's correct. Medical research can be frustratingly slow, but we are at an
0:59
incredibly exciting time in the cure focus space for spinal cord injury. Now, we've been promoting and funding a cure for spinal cord injury for about 30 years, and in the past ten years, there have been incredible breakthroughs in the science, particularly in an area called Neurostimulation, which in overseas studies we've seen trial volunteers stand up, take steps, return of internal bodily functions that have become lost after an accident. And this is in a context where you have an absolutely devastating condition and globally, no cure and no treatment whatsoever. And we have collaborated with Australia's spinal cord injury specialist to create something called Project Spark, and that is a series of clinical trials that's rigorously testing neurostimulation. And the aim is to provide the evidence necessary for regulatory approval. And we hope in a matter of years, we'll have something ready for
1:59
mainstream. And, Paul, I mean, your background is investing and you're now the CEO of Hearts and Minds. Tell us how important this work is for you and why it is so significant to partner with NPS. Yeah. So a recap of hearts and minds, if that's all right. So hearts and minds listed investment company. We invest in global equities that are chosen by selected fund managers. But the difference is there's no investment fees. So instead of investment fees we donate 1.5% of the value of the company to medical research each year. And that's running at about $10 million a year. And we've raised about 65 million since inception. And Spinal Cure Australia is the latest beneficiary of that investment. And we the way we direct our research dollars is we direct research to organisations that have big invest, you know, big research ideas, chances where there really is a chance of a breakthrough or an improvement in diagnosis, treatment or quality of life in the near term. And
2:59
I we're pretty confident that spinal Cure is one of those organisations that will make a difference to people that have a spinal cord injury. So, as you say, investing without the need to pay fees to an investment manager. So tell us a little bit more about how hearts and minds has been going. I guess, you know, in terms of your own, um, investments, but also on the, on the market. Yeah. So, um, hearts and minds, we've had an investment return. The beauty of the model is there is no trade off between the commercial return and the social returns. So our investment return has been 9% per annum since inception. We also pay a 5.5% fully franked dividend to our shareholders, which is sustainable. And as I said, there is no, uh, investment fees because fund managers give their time and expertise and stock recommendations for free, and that enables the organisation to donate 1.5%, or about $10 million a year, to medical research. Our recent investment performance is very good.
3:59
We've had long term holdings in in Microsoft, Mastercard, Amazon, um, internet, Intercontinental Exchange, um, and they've been very good long term holdings for us. And more recently we've been really into the semiconductor and AI space. We've held Nvidia for a year or so, next DC, next DC here in Australia and Taiwan Semiconductor. So recent performance is pretty good. And we're up 18% in the last six months. In terms of that theme. I mean, Nvidia of course is the story of the day really. How much is I, I guess driving investments as well and potentially even AI being used for research and for finding cures like, um, spinal injuries. Yeah, that's a big question. I is no doubt, um, driving demand for semiconductor stocks like Nvidia and Taiwan Semiconductor. But with some of our beneficiaries we've seen are being used very much in medical research,
4:58
particularly in. Imaging research and diagnosis and treatment. It has proven to be more accurate often than, you know, physical doctors. I'm not sure what it's being used at spinal cord, but it really has a role for health care. I. Well, the technology that we use is a small medical device which attaches electrodes to the skin and delivers electrical pulses, which, coupled with exercise therapy, wakes up that connection between brain and body. It's pretty astounding how it works. But if we're talking AI, we need to refer to Elon Musk. And he's got a clinical trial going on at the moment with a thousand quadriplegics have signed up for. And he's implanted a brain chip into the first quadriplegic. And that trial volunteer can now play video games with his mind. Wow. That's fascinating. Tell us a little bit more about the partnership here. How did you guys sort of come to meet or how did you get involved with hearts and
5:58
minds? Yeah, the way Hearts and Minds chooses its medical research beneficiary, a bit like the way we choose our fund managers. We look for medical research organizations that are very focused in a particular area of research. As spinal cure is, we look for a track record of of quality research and, and publications and citations, but we also favor organizations that are probably not the big ones that already are well funded by by government. We we prefer, you know, second tier where philanthropic given giving can really make a difference to some of the clinical trials. And we find if hearts and minds seeds initial funding in research, it's leveraged then for government funding and has a multiplier effect. So it really so taking a risk on more innovative research does attract other funders to the space. And we can multiply our impact 3 or 4 times. And you mentioned there government funding. We just had the federal
6:58
budget. Kathryn, do you think enough was allocated to areas like yours? Well, we didn't have our iron in that fire this time round, but in previous rounds, we did lobby the federal government. And Greg Hunt established a $10 million fund for cure for spinal cord injury research, which had never been done before. And probably that's something will be aiming for in the next budget. Is there a timeline in our lifetimes where we will see a cure?
7:28
A cure, certainly in the next few years and progressively in increments, we will see mainstream therapies available that will return feeling and function for people with spinal cord injuries a cure. Global experts are saying neurostimulation will be a vital, pivotal part of that cure and likely to be a combination of experimental therapies. So we might see
7:54
Elon Musk's brain chip compared with exercise rehab and neurostimulation and maybe some stem cell and scaffold work a cure in this lifetime. It could be possible with the right kind of funding and the right kind of backers, because really, at the end of the day, it's about funding. And yes, of course it's about time. Yeah. And we obviously know you've committed funding for $100,000 over two years, but just putting your investment hat on, just finally pull your view on the overall macro environment where we're facing these higher for longer interest rates. I know you've got a long investment career behind you. Yeah, that long investment career has made me know not to make forecasts or outlook. Um, yeah, I, I won't make a comment on on the outlook. Um, we will focus on choosing good fund managers that are very good at choosing high conviction stock picks. And that'll give us the best chance to perform for our shareholders, in which
8:54
case creates value, then to distribute to great organizations like Spinal Cure.